PRINCETON, N.J., November 30, 2021 (Newswire.com) - Enalare Therapeutics Inc., a biopharmaceutical company dedicated to developing novel therapies for patients suffering from life threatening critical care conditions, announced today that it has filed a Provisional Patent Application with the United States Patent and Trademark Office on its lead product ENA-001 and related compounds for the reversal of respiratory depression from non-opioid central nervous system depressants, including common surgical anesthetics. Any resultant patent claiming priority to this filing will have an estimated term to 2042.
"We are excited to have filed this important new patent application for ENA-001," stated Daniel Motto, Enalare's Chief Operating Officer. "This is an important milestone for our unique new chemical entity and builds upon an already strong basis of existing intellectual protection, including multiple composition of matter patents. We look forward to filing additional patent applications as we further develop ENA-001 to address unmet medical needs across multiple settings."
Enalare's lead product, ENA-001, is a one-of-a-kind new chemical entity (NCE) designed as an agnostic respiratory stimulant. The product has a unique mechanism of action that affects ventilation via the peripheral chemoreceptor pathway in the carotid bodies. The product utilizes the body's own ventilation control system to beneficially influence breathing and has been shown to be effective and well tolerated in four previous human studies. The Company recently announced the dosing of the first subject in a breakthrough study evaluating the ability of ENA-001 to reverse the respiratory depressive effects of propofol, a commonly utilized anesthetic in surgical procedures.
About Enalare Therapeutics Inc.
Enalare Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients suffering from life threatening acute respiratory and critical care conditions, including drug overdose, post-surgery respiratory depression, and apnea of prematurity. The Company is planning to initiate additional clinical studies for ENA-001 across multiple indications in the coming year.
Enalare Investor Relations